Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
In Lexington, Massachusetts on March 12, 2026, Curis, Inc. disclosed plans to disclose its financial results for the final quarter of 2025. The biotech firm, trading as CRIS on NASDAQ, specializes in advancing emavusertib (CA-4948), a medication that acts as an IRAK4 and FLT3 inhibitor. This orally administered, small molecule has garnered considerable attention for its potential therapeutic benefits.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments